Experience of padma 28 in multiple sclerosis
ABSTRACT One hundred subjects suffering from a chronic progressive form of multiple sclerosis were randomly divided into two equal groups. Group 1 received Padma 28, two tablets three times a day, and group 2, the control, were treated only symptomatically. Treatment and observation lasted for 1 year. Examinations performed directly prior to the study and in the course of observation included: neurological state, visual and auditory evoked potentials, basic laboratory tests. A positive effect of Padma 28 was observed in 44% of patients with multiple sclerosis in the form of improvement of general condition, increase of muscle strength, decrease or disappearance of disorders affecting sphincters. In 41% of patients with initially an abnormal tracing of visual evoked potentials, an improvement or normalization was achieved. Of patients, who did not receive Padma 28 none felt better, moreover, 40% of them showed a deterioration. Tolerance of the drug was excellent.
SourceAvailable from: Tawni Tidwell[Show abstract] [Hide abstract]
ABSTRACT: Introduction: Tibetan medicine (TM) is a whole systems medical approach that has had growing interest in the West. However, minimal research, particularly with cancer, has been conducted. The purpose of this article is to provide an overview of TM and describe a clinical case review study to obtain preliminary evidence of TM's safety and effect on patients treated for cancer or hematologic disorders. Methods: A retrospective case review was conducted in India and cases met the following inclusion criteria: (a) confirmed diagnosis of cancer or hematologic disorder by standard Western biomedical diagnostic tests, (b) either treated exclusively with TM or received insufficient Western treatment followed by TM and (c) were in remission or had stable disease at least 2 years after start of TM. Results: Three cases were identified, 1 solid tumor and 2 hematologic diseases: Case 1-poorly to moderately differentiated adenocarcinoma of the stomach, positive lymph nodes and mucosal infiltration, with clear scans and excellent quality of life 29 months later ; Case 2-chronic myelogenous leukemia with normalization of hematologic labs within 3 months of starting TM and stable 4 years later; and Case 3-red cell aplasia improved significantly and reversed dependence on blood transfusions with TM. None of the cases experienced demonstrable adverse effects from TM. Conclusions: This limited case review found TM to be safe and have positive effects on quality of life and disease regression and remission in patients with cancer and blood disorders. Further exploration and investigation using rigorous methods is warranted.Integrative Cancer Therapies 09/2014; 13(6). DOI:10.1177/1534735414549624 · 2.01 Impact Factor
Article: Multiple Sclerosis[Show abstract] [Hide abstract]
ABSTRACT: Multiple sclerosis (MS) is a chronic progressive demyelinating disease of the central nervous system. Common manifestations include paresthesias, diplopia, loss of vision, numbness or weakness of the limbs, bowel or bladder dysfunction, spasticity, ataxia, fatigue, and mental changes. Four main patterns of MS are recognized: relapsing remitting, primary progressive, secondary progressive, and progressive relapsing. The cause of MS is unknown, although it appears to be an autoimmune disease. Much of what is known about MS has been learned from an animal model of the disease, experimental allergic encephalomyelitis.01/2013; 2(1):50-56. DOI:10.7453/gahmj.2013.2.1.009